IRIS
TORTORA, GIAMPAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.678
NA - Nord America 3.646
EU - Europa 2.640
SA - Sud America 431
AF - Africa 103
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 1
Totale 10.503
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.494
SG - Singapore 1.717
RU - Federazione Russa 1.203
VN - Vietnam 690
CN - Cina 672
UA - Ucraina 379
BR - Brasile 346
HK - Hong Kong 293
DE - Germania 217
IT - Italia 183
FR - Francia 145
FI - Finlandia 131
CA - Canada 97
NL - Olanda 96
GB - Regno Unito 82
SE - Svezia 71
IE - Irlanda 65
IN - India 47
BD - Bangladesh 45
JP - Giappone 39
AR - Argentina 32
CI - Costa d'Avorio 32
MX - Messico 29
ZA - Sudafrica 23
PH - Filippine 22
PL - Polonia 21
KR - Corea 20
PK - Pakistan 19
IQ - Iraq 17
EC - Ecuador 15
MA - Marocco 14
TW - Taiwan 14
ID - Indonesia 13
CO - Colombia 11
TH - Thailandia 11
VE - Venezuela 11
ES - Italia 9
PY - Paraguay 8
TN - Tunisia 8
UZ - Uzbekistan 8
AT - Austria 6
DZ - Algeria 6
EG - Egitto 6
AE - Emirati Arabi Uniti 5
BE - Belgio 5
CL - Cile 5
JM - Giamaica 5
JO - Giordania 5
LB - Libano 5
NP - Nepal 5
TT - Trinidad e Tobago 5
IL - Israele 4
KH - Cambogia 4
NI - Nicaragua 4
LT - Lituania 3
MY - Malesia 3
PE - Perù 3
PS - Palestinian Territory 3
PT - Portogallo 3
SA - Arabia Saudita 3
TR - Turchia 3
BA - Bosnia-Erzegovina 2
BB - Barbados 2
BY - Bielorussia 2
CD - Congo 2
CH - Svizzera 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
EU - Europa 2
MD - Moldavia 2
PR - Porto Rico 2
RO - Romania 2
RS - Serbia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
ZW - Zimbabwe 2
AL - Albania 1
AZ - Azerbaigian 1
BH - Bahrain 1
BW - Botswana 1
BZ - Belize 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
ET - Etiopia 1
GD - Grenada 1
GE - Georgia 1
GH - Ghana 1
GI - Gibilterra 1
GR - Grecia 1
IR - Iran 1
KW - Kuwait 1
KY - Cayman, isole 1
KZ - Kazakistan 1
LV - Lettonia 1
LY - Libia 1
MQ - Martinica 1
MR - Mauritania 1
MU - Mauritius 1
MW - Malawi 1
Totale 10.494
Salva come PNG Salva come JPEG
Città #
Singapore 775
San Jose 495
Jacksonville 367
Moscow 325
Chandler 301
Hong Kong 278
Beijing 262
Ashburn 241
Ho Chi Minh City 202
Hanoi 150
Millbury 133
Santa Clara 118
Los Angeles 92
Woodbridge 89
Lauterbourg 86
Amsterdam 84
Princeton 84
The Dalles 82
Munich 64
Buffalo 61
Wilmington 60
Nanjing 56
Ottawa 53
New York 45
Boston 39
São Paulo 38
Haiphong 32
Ann Arbor 31
Dallas 31
Tokyo 31
Boardman 28
Da Nang 28
Houston 28
Council Bluffs 27
Nanchang 25
Naples 25
Hefei 24
Turku 19
Norwalk 18
Warsaw 17
Orem 16
Rio de Janeiro 16
Montreal 15
Shenyang 15
Stockholm 15
Atlanta 14
Chicago 14
Biên Hòa 13
Kronberg 13
Brooklyn 12
Hebei 12
Helsinki 12
London 12
Mexico City 12
Changsha 11
Denver 11
Frankfurt am Main 11
Phoenix 11
Redondo Beach 11
Rome 11
San Francisco 11
Tianjin 11
Can Tho 10
Casablanca 10
Islamabad 10
Johannesburg 10
Chennai 9
Poplar 9
Seattle 9
Guangzhou 8
Hải Dương 8
Tashkent 8
Baghdad 7
Belo Horizonte 7
Bắc Ninh 7
Porto Alegre 7
Thái Bình 7
Brasília 6
Bắc Giang 6
Dhaka 6
Jiaxing 6
Kunming 6
Memphis 6
Quận Bình Thạnh 6
Amman 5
Dublin 5
Falkenstein 5
Guarulhos 5
Manchester 5
Manila 5
Milan 5
Ninh Bình 5
Nuremberg 5
Quận Ba 5
Toronto 5
Uberlândia 5
Washington 5
Bangkok 4
Bengaluru 4
Bogotá 4
Totale 5.468
Salva come PNG Salva come JPEG
Nome #
Manuale di Oncologia Clinica 234
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. 156
BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making 152
Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. 149
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study. 142
Paraneoplastic sensitive neuropathy associated with anti-hu antibodies in a neuroendocrine tumor of duodenum: a case report. 142
Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. 140
Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. 139
Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. 137
A novel thyroid transcript negatively regulated by TSH. 137
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases 132
Enzastaurin inhibits tumors sensitive and resistant to anti-EGFR drugs 132
Inhibition of growth factors production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. 130
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. 129
Antiangiogenic and antitumor activity of anti-EGFR C225 monoclonal antibody in combination with Vascular Endothelial Growth Factor antisense oligonucleotide in human GEO colon cancer cells. 127
Cyclic AMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors. 126
Phase I clinical trial of high dose recombinant interleukin-2/veparimil combination in advancer cancer. 125
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. 123
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors. 122
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. 122
Therapeutic integration of signal transduction targeting agents and conventional anti-cancer treatments. 121
EGFR antagonists in cancer treatment. 121
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor. 118
The mechanisms of resistance to EGFR inhibitors. 117
Combination of biological therapies in non-small cell lung cancer. 116
A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action 116
Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. 115
Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. 114
Angiogenesis: A target for cancer therapy. 112
Anti-epidermal growth factor receptor drugs in cancer therapy. 112
Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-lerm follow-up. 112
The use of xenograft models for the selection of cancer treatments with the EGFR as an example. 112
A novel mdm2 antisense oligonucleotide has antitumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. 111
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 110
MONOCLONAL ANTIBODIES TARGETING THE EPIDERMAL GROWTH FACTOR RECEPTOR. 110
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. 110
Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumour activity with EGFR inhibitors 110
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective EGFR-tyrosine kinase inhibitor ZD1839 (‘Iressa’) 109
Combined targeted inhibition of Bcl-2, Bcl-xL, EGFR and Protein Kinase A Type I causes potent antitumor, apoptotic and antiangiogenic activity 108
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. 107
8-Chloro-cyclic AMP inhibits autocrine and angiogenic growth factor production in human colorectal and breast cancer. 107
Altri tumori gastrointestinali 107
Overexpression of wild-type p53 ovverrides the mitogenic effect of the RIa subunit of protein kinase A in human breast cells. 104
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. 104
Down-regulation of type I protein kinase A by transfection of human breast cancer cells with an epidermal growth factor receptor antisense expression vector. 104
Key cancer cell signal transduction pathways as therapeutic targets. 102
Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. 102
Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis and cooperates with cytotoxic drugs in human cancer cell lines. 101
Cooperative antitumor effect of mixed backbone oligonucleotides targeting protein kinase A in combination with cytotoxic drugs or biologic agents. 101
Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. 101
Antitumor effects of ZD6474, a small molecule Vascular Endothelial Growth Factor receptor tyrosine kinase inhibitor, with additional activity against Epidermal Growth Factor. 99
Strategies for multiple signalling inhibition. 99
Mitoxantrone, etoposide and bleomycin (MEB) chemotherapy in non-Hodgkin's lymphoma patients non-elegible for standard cyclophoshamide, doxorubicin, vincristine and prednisone (CHOP) combination. 98
CHEMOSENSITIZATION BY ANTISENSE OLIGONUCLEOTIDES TARGETING MDM2. 97
Novel TLR9 agonist induces EGFR inhibition and synergistic antitumor activity with EGFR inhibitors. 95
INTRINSIC AND ACQUIRED RESISTANCE TO EGFR INHIBITORS IN HUMAN CANCER THERAPY. 95
Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. 94
Combined blockade of PKA and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis. 94
TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts. 93
Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies. 93
8-Chloro-cAMP inhibits smooth muscle cell proliferation in vitro and neointima formation induced by ballon injury in vivo. 93
Inhibition of bcl-2 as cancer therapy. 93
ZD1839 (Iressa): preclinical studies and pharmacology. 93
Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. 93
Expression of biomarkers modulating prostate cancer progression: Implications in the treatment of the disease 93
ANTITUMOR ACTIVITY OF ZD6474, A VEGFR-2 AND EGFR SMALL MOLECULE TYROSINE KINASE INHIBITOR, IN COMBINATION WITH SC-236, A CYCLOOXYGENASE-2 INHIBITOR. 91
Differential sensitivity to non-MHC-restricted rIL-2 activated lymphocyte killing of human mammary epithelial MCF-10A cells overexpressing oncogenes or PKA subunits. 91
ZD1839 (‘Iressa’), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells. 90
Preclinical and phase I study of oxaliplatin and topotecan in combination in human cancer. 89
The rationale for the combination of selective EGFR inhibitors with cytotoxic drugs and radiotherapy. 88
Combined targeting of EGFR and VEGF-dependent pathways: rationale, preclinical studies and clinical applications 88
EGFR-targeting agents in oncology 88
Oral antisense targeting protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis and growth factors production. 86
8-Chloro-cAMP enhances the growth inhibitory effect of cytotoxic drugs in human colon cancer cells 86
Effect of thymic extract "thymostimulin" on the incidence of infections and myelotoxicity during adjuvant chemotherapy for breast cancer. 86
ANTITUMOR ACTIVITY OF THE COMBINATION OF CETUXIMAB, AN ANTI-EGFR BLOCKING MONOCLONAL ANTIBODY AND ZD6474, AN INHIBITOR OF VEGFR AND EGFR TYROSINE KINASES. 85
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. 83
Targeting of Epidermal Growth Factor Receptor and Protein Kinase A : Molecular basis and therapeutic applications. 83
Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting Protein Kinase A in combination with docetaxel and anti-EGFR-Receptor antibody on human breast cancer cell growth. 81
Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting protein kinase A. 81
The cAMP-dependent protein kinase type I is involved in hypersensitivity of human breast cells to topoisomerase II inhibitors. 81
The RIalpha subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor. Oncogene. 1997 Feb 27;14(8):923-8. 80
Effects of mutant p53 genes on transformation of human mammary epithelial cells. 80
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 78
Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer. 78
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy. 77
Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst. 1996 Dec 4;88(23):1770-6. 77
Phase I clinical study with 8-Chloro-cAMP and evaluation of immunological effects in cancer patients. 77
Expression of epidermal growth factor receptor (EGFR) correlates with disease relapse and progression to androgen-indepedence in human prostate cancer 74
Differential effects of type I and type II protein kinase A isoforms on chinese hamster ovary cell cycle and proliferation. 74
Inhibition of Cripto expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides. 72
Synergistic growth inhibition and induction of apoptosis by a novel mixed backbone antisense oligonuclotide targeting CRIPTO in combination with C225 anti-EGFR monoclonal antibody and 8-Cl-cAMP in human GEO colon cancer cells. 70
Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumors sensitive and resistant to anti-EGFR drugs 70
Differential immunohistochemical detection of transforming growth factor , amphiregulin and CRIPTO in human normal and malignant breast tissues. 70
Mechanisms of resistance to HER/erbB inhibitors 70
Helicobacter pylori VacA toxin up-regulates Vascular endothelial growth factor expression in MKN 28 gastric cells through an Epidermal growth factor receptor-, Cyclooxygenase-2-dependent mechanism 67
LY2109761, a Novel Transforming Growth Factor ß Receptor type I and II dual inhibitor, as a Therapeutic Approach to Suppressing Pancreatic Cancer Metastasis. 67
In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches. 65
Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. 61
Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. 58
Totale 10.254
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.252
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.252
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022516 12 2 2 8 9 9 8 18 68 30 138 212
2022/2023656 95 80 21 40 72 73 6 48 90 84 36 11
2023/2024412 16 64 32 67 19 23 16 55 10 6 79 25
2024/20252.556 140 172 7 9 85 68 290 140 172 258 963 252
2025/20264.800 592 366 458 413 857 202 482 263 636 328 93 110
2026/202777 77 0 0 0 0 0 0 0 0 0 0 0
Totale 10.579